Levoleucovorin inhibits LOXL2 (lysyl oxidase like-2) to control breast cancer proliferation: a repurposing approach

References

• Abohassan, M., Alshahrani, M., Alshahrani, M. Y., & Rajagopalan, P. (2022). Insilco and invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations. Medical Oncology (Northwood, London, England), 39(12), 249. https://doi.org/10.1007/s12032-022-01846-1
   PubMed Web of Science ®Google Scholar
• Aggarwal, S., Verma, S. S., Aggarwal, S., & Gupta, S. C. (2021). Drug repurposing for breast cancer therapy: Old weapon for new battle. Semin Cancer Biol, 68, 8–20. https://doi.org/10.1016/j.semcancer.2019.09.012
   PubMed Web of Science ®Google Scholar
• Ahn, S. G., Dong, S. M., Oshima, A., Kim, W. H., Lee, H. M., Lee, S. A., Kwon, S. H., Lee, J. H., Lee, J. M., Jeong, J., Lee, H. D., & Green, J. E. (2013). LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Research and Treatment, 141(1), 89–99. https://doi.org/10.1007/s10549-013-2662-3
   PubMed Web of Science ®Google Scholar
• Baid, R., & Agarwal, R. (2018). Flibanserin: A controversial drug for female hypoactive sexual desire disorder. Industrial Psychiatry Journal, 27(1), 154–157. https://doi.org/10.4103/ipj.ipj_20_16
   PubMedGoogle Scholar
• Baker, A. M., Bird, D., Lang, G., Cox, T. R., & Erler, J. T. (2013). Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene, 32(14), 1863–1868. https://doi.org/10.1038/onc.2012.202
   PubMed Web of Science ®Google Scholar
• Chuang, V. T., & Suno, M. (2012). Levoleucovorin as replacement for leucovorin in cancer treatment. The Annals of Pharmacotherapy, 46(10), 1349–1357. https://doi.org/10.1345/aph.1Q677
   PubMed Web of Science ®Google Scholar
• DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019). Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(6), 438–451. https://doi.org/10.3322/caac.21583
   PubMed Web of Science ®Google Scholar
• Dinca, S. C., Greiner, D., Weidenfeld, K., Bond, L., Barkan, D., & Jorcyk, C. L. (2021). Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment. Breast Cancer Research: BCR, 23(1), 56. https://doi.org/10.1186/s13058-021-01430-x
   PubMed Web of Science ®Google Scholar
• Ferreira, S., Saraiva, N., Rijo, P., & Fernandes, A. S. (2021). LOXL2 inhibitors and breast cancer progression. Antioxidants (Basel), 10(2), 312. https://doi.org/10.3390/antiox10020312
   PubMedGoogle Scholar
• Hutchinson, J. H., Rowbottom, M. W., Lonergan, D., Darlington, J., Prodanovich, P., King, C. D., Evans, J. F., & Bain, G. (2017). Small molecule lysyl oxidase-like 2 (LOXL2) inhibitors: The identification of an inhibitor selective for LOXL2 over LOX. ACS Medicinal Chemistry Letters, 8(4), 423–427. https://doi.org/10.1021/acsmedchemlett.7b00014
   PubMed Web of Science ®Google Scholar
• Maldonado, V., & Melendez-Zajgla, J. (2022). The role of hypoxia-associated long non-coding RNAs in Breast Cancer. Cells, 11(10), 1679. https://doi.org/10.3390/cells11101679
   PubMed Web of Science ®Google Scholar
• Miana, M., Galán, M., Martínez-Martínez, E., Varona, S., Jurado-López, R., Bausa-Miranda, B., Antequera, A., Luaces, M., Martínez-González, J., Rodríguez, C., & Cachofeiro, V. (2015). The lysyl oxidase inhibitor β-aminopropionitrile reduces body weight gain and improves the metabolic profile in diet-induced obesity in rats. Disease Models & Mechanisms, 8(6), 543–551. https://doi.org/10.1242/dmm.020107
   PubMed Web of Science ®Google Scholar
• Miller, B. R., 3rd, McGee, T. D., Jr., Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012). MMPBSA.py: An efficient program for end-state free energy calculations. Journal of Chemical Theory and Computation, 8(9), 3314–3321. https://doi.org/10.1021/ct300418h
   PubMed Web of Science ®Google Scholar
• Moon, H. J., Finney, J., Ronnebaum, T., & Mure, M. (2014). Human lysyl oxidase-like 2. Bioorganic Chemistry, 57, 231–241. https://doi.org/10.1016/j.bioorg.2014.07.003
   PubMed Web of Science ®Google Scholar
• Saif, A., Al Shahrani, M., Alshehri, M., Abohassan, M., Alshehri, M. A., Radhakrishnan, S., & Rajagopalan, P. (2022). Biotechnology and Applied Biochemistry.
   Google Scholar
• Salvador, F., Martin, A., López-Menéndez, C., Moreno-Bueno, G., Santos, V., Vázquez-Naharro, A., Santamaria, P. G., Morales, S., Dubus, P. R., Muinelo-Romay, L., López-López, R., Tung, J. C., Weaver, V. M., Portillo, F., & Cano, A. (2017). Lysyl oxidase-like protein LOXL2 promotes lung metastasis of breast cancer. Cancer Research, 77(21), 5846–5859. https://doi.org/10.1158/0008-5472.CAN-16-3152
   PubMed Web of Science ®Google Scholar
• Semenza, G. L. (2012). Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends in Molecular Medicine, 18(9), 534–543. https://doi.org/10.1016/j.molmed.2012.08.001
   PubMed Web of Science ®Google Scholar
• Shati, A. A., Eid, R. A., Zaki, M. S. A., Alqahtani, Y. A., Al-Qahtani, S. M., & Chandramoorthy, H. C. (2022). Lycopene scavenges cellular ROS, modulates autophagy and improves survival through 7SK snRNA interaction in smooth muscle cells. Cells, 11(22), 3617. https://doi.org/10.3390/cells11223617
   PubMed Web of Science ®Google Scholar
• Sousa da Silva, A. W., & Vranken, W. F. (2012). ACPYPE – AnteChamber PYthon Parser interfacE. BMC Research Notes, 5, 367. https://doi.org/10.1186/1756-0500-5-367
   PubMedGoogle Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455.
   PubMed Web of Science ®Google Scholar
• Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A., & Moreno, E. (2021). gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. Journal of Chemical Theory and Computation, 17(10), 6281–6291. https://doi.org/10.1021/acs.jctc.1c00645
   PubMed Web of Science ®Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Wang, C., Xu, S., Tian, Y., Ju, A., Hou, Q., Liu, J., Fu, Y., & Luo, Y. (2019). Lysyl oxidase-like protein 2 promotes tumor lymphangiogenesis and lymph node metastasis in breast cancer. Neoplasia (New York, N.Y.), 21(4), 413–427. https://doi.org/10.1016/j.neo.2019.03.003
   PubMed Web of Science ®Google Scholar
• Xiao, Q., & Ge, G. (2012). Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenvironment: Official Journal of the International Cancer Microenvironment Society, 5(3), 261–273. https://doi.org/10.1007/s12307-012-0105-z
   PubMedGoogle Scholar
• Yang, N., Cao, D. F., Yin, X. X., Zhou, H. H., & Mao, X. Y. (2020). Lysyl oxidases: Emerging biomarkers and therapeutic targets for various diseases. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 131, 110791. https://doi.org/10.1016/j.biopha.2020.110791
   PubMed Web of Science ®Google Scholar
• Yuuki, S., Komatsu, Y., Fuse, N., Kato, T., Miyagishima, T., Kudo, M., Watanabe, M., Tateyama, M., Kunieda, Y., Wakahama, O., Sakata, Y., & Asaka, M. (2010). Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: Results of phase I and II studies. Clinical Drug Investigation, 30(4), 243–249. https://doi.org/10.2165/11534470-000000000-00000
   PubMed Web of Science ®Google Scholar